Item 2.02 Results of Operations and Financial Condition.

On January 13, 2021, Adamas Pharmaceuticals, Inc. (the "Company") issued a press release announcing certain preliminary financial results for the fourth quarter and full year ended December 31, 2020. The Company's financial statements for the fourth quarter and full year ended December 31, 2020, have not yet been completed and could result in changes to these preliminary financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits
Exhibit No.             Description
  99.1                  99.1 Press Release dated January 13, 2021.
104                     Cover Page Interactive Data File (embedded within the Inline XBRL document).



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses